Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Poster Presentations: Clinical Diabetes/Therapeutics

1175-P: Racial Difference in Diabetes Medication Initiation

  1. AARON N. WINN,
  2. ANDREW J. KARTER,
  3. ERIN M. STAAB,
  4. JENNIFER LIU,
  5. WEN WAN,
  6. REZA SKANDARI,
  7. ALEXANDRA C. KNITTER,
  8. HOWARD H. MOFFET,
  9. DONALD R. MILLER,
  10. MONICA E. PEEK,
  11. ELBERT HUANG and
  12. NEDA LAITEERAPONG
  1. Milwaukee, WI, Oakland, CA, London, United Kingdom, Westford, MA, Chicago, IL
Diabetes 2020 Jun; 69(Supplement 1): -. https://doi.org/10.2337/db20-1175-P
Previous
  • Article
  • Figures & Tables
  • Info & Metrics
Loading

Abstract

Objective: We examined how diabetes medication initiation after first diagnosis varied by race/ethnicity.

Method: We conducted a retrospective cohort study of 66,939 patients with newly diagnosed diabetes using data from a large integrated healthcare system. We classified patients into 12 race/ethnicity groups (see Table) and assessed their associations with diabetes medication initiation within 1, 12 and 18 months after diagnosis. We used a modified Poisson regression to estimate risk ratios adjusted for pre-diagnosis demographics and clinical characteristics.

Results: Medications were started in 30%, 43% and 48% of patients within 1, 12 and 18 months, respectively. Within 1 month of diagnosis, Chinese, Filipino, and Native Hawaiian/Pacific islander were less likely to initiate a medication compared to whites. Results were consistent at 12 and 18 months, except that Japanese and blacks/African Americans were less likely to initiate compared to whites and that there was no difference between Native Hawaiian/Pacific islanders and whites at 18 months.

Conclusions: We observed persistent racial differences between patients receiving any medication following initial diabetes diagnosis, with the largest differences for several Asian populations.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Disclosure A.N. Winn: None. A.J. Karter: Research Support; Self; Dexcom, Inc. E.M. Staab: None. J. Liu: None. W. Wan: None. R. Skandari: None. A.C. Knitter: None. H.H. Moffet: None. D.R. Miller: None. M.E. Peek: Research Support; Self; Merck Foundation. E. Huang: None. N. Laiteerapong: None.

  • © 2020 by the American Diabetes Association
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

Previous
Back to top
Diabetes: 69 (Supplement 1)

In this Issue

June 2020, 69(Supplement 1)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
1175-P: Racial Difference in Diabetes Medication Initiation
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
1175-P: Racial Difference in Diabetes Medication Initiation
AARON N. WINN, ANDREW J. KARTER, ERIN M. STAAB, JENNIFER LIU, WEN WAN, REZA SKANDARI, ALEXANDRA C. KNITTER, HOWARD H. MOFFET, DONALD R. MILLER, MONICA E. PEEK, ELBERT HUANG, NEDA LAITEERAPONG
Diabetes Jun 2020, 69 (Supplement 1) 1175-P; DOI: 10.2337/db20-1175-P

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

1175-P: Racial Difference in Diabetes Medication Initiation
AARON N. WINN, ANDREW J. KARTER, ERIN M. STAAB, JENNIFER LIU, WEN WAN, REZA SKANDARI, ALEXANDRA C. KNITTER, HOWARD H. MOFFET, DONALD R. MILLER, MONICA E. PEEK, ELBERT HUANG, NEDA LAITEERAPONG
Diabetes Jun 2020, 69 (Supplement 1) 1175-P; DOI: 10.2337/db20-1175-P
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Tables
  • Info & Metrics

Related Articles

Cited By...

More in this TOC Section

Poster Presentations: Clinical Diabetes/Therapeutics

  • 1374-P: Association between Number of Abnormal Glucose Values and Severity of Fasting Plasma Glucose in IADPSG Criteria and Pregnancy Outcomes in Pregnant Women in South India
  • 1369-P: Is Weight Loss after a Pregnancy Complicated by Diabetes Associated with Improved Subsequent Pregnancy Outcomes?
  • 1320-P: Building Trust between Researchers and African American and Latino Families of Children with T1D to Enhance Recruitment, Retention, and the Relevance of Research
Show more Poster Presentations: Clinical Diabetes/Therapeutics

P: Health Care Delivery—Quality Improvement

  • 1209-P: A Quality Improvement Initiative to Increase Utilization of Continuous Glucose Monitors Results in Improved Glycemic Outcomes in a Pediatric Diabetes Clinic
  • 1230-P: Advantages of Network-Based Blood Glucose Team Management on Hyperglycemic Patients in Noncritical Units
  • 1228-P: Health Care Avoidance and Diabetes-Related Care among Medicare Beneficiaries with Type 2 Diabetes
Show more P: Health Care Delivery—Quality Improvement

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.